164 related articles for article (PubMed ID: 35691608)
1. A Full Target-Mediated Drug Disposition (TMDD) Model to Explain the Changes in Recombinant Human Erythropoietin (rhEpo) Pharmacokinetics in Patients with Different Bone Marrow Integrity Following Hematopoietic Transplantation.
Wu N; Widness JA; Yan X; Veng-Pedersen P; An G
J Pharm Sci; 2022 Sep; 111(9):2620-2629. PubMed ID: 35691608
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers.
Krzyzanski W; Wyska E
Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):637-45. PubMed ID: 18071675
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic analysis of continuous erythropoietin receptor activator disposition in adult sheep using a target-mediated, physiologic recirculation model and a tracer interaction methodology.
El-Komy MH; Widness JA; Veng-Pedersen P
Drug Metab Dispos; 2011 Apr; 39(4):603-9. PubMed ID: 21209249
[TBL] [Abstract][Full Text] [Related]
4. Skin regeneration with conical and hair follicle structure of deep second-degree scalding injuries via combined expression of the EPO receptor and beta common receptor by local subcutaneous injection of nanosized rhEPO.
Bader A; Ebert S; Giri S; Kremer M; Liu S; Nerlich A; Günter CI; Smith DU; Machens HG
Int J Nanomedicine; 2012; 7():1227-37. PubMed ID: 22419870
[TBL] [Abstract][Full Text] [Related]
5. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP.
Jelkmann W
Eur J Haematol; 2002; 69(5-6):265-74. PubMed ID: 12460230
[TBL] [Abstract][Full Text] [Related]
6. Differential pharmacokinetic analysis of in vivo erythropoietin receptor interaction with erythropoietin and continuous erythropoietin receptor activator in sheep.
El-Komy MH; Schmidt RL; Widness JA; Veng-Pedersen P
Biopharm Drug Dispos; 2011 Jul; 32(5):276-88. PubMed ID: 21678432
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro.
Våtsveen TK; Sponaas AM; Tian E; Zhang Q; Misund K; Sundan A; Børset M; Waage A; Brede G
J Hematol Oncol; 2016 Aug; 9(1):75. PubMed ID: 27581518
[TBL] [Abstract][Full Text] [Related]
8. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.
Yan X; Mager DE; Krzyzanski W
J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):25-47. PubMed ID: 20012173
[TBL] [Abstract][Full Text] [Related]
9. Targeted near-infrared imaging of the erythropoietin receptor in human lung cancer xenografts.
Doleschel D; Mundigl O; Wessner A; Gremse F; Bachmann J; Rodriguez A; Klingmüller U; Jarsch M; Kiessling F; Lederle W
J Nucl Med; 2012 Feb; 53(2):304-11. PubMed ID: 22228796
[TBL] [Abstract][Full Text] [Related]
10. Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO).
Woo S; Krzyzanski W; Jusko WJ
J Pharmacokinet Pharmacodyn; 2007 Dec; 34(6):849-68. PubMed ID: 17943422
[TBL] [Abstract][Full Text] [Related]
11. Change in erythropoietin pharmacokinetics following hematopoietic transplantation.
Widness JA; Schmidt RL; Hohl RJ; Goldman FD; Al-Huniti NH; Freise KJ; Veng-Pedersen P
Clin Pharmacol Ther; 2007 Jun; 81(6):873-9. PubMed ID: 17429351
[TBL] [Abstract][Full Text] [Related]
12. Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics.
Chapel SH; Veng-Pedersen P; Schmidt RL; Widness JA
Exp Hematol; 2001 Apr; 29(4):425-31. PubMed ID: 11301182
[TBL] [Abstract][Full Text] [Related]
13. Evidence of receptor-mediated elimination of erythropoietin by analysis of erythropoietin receptor mRNA expression in bone marrow and erythropoietin clearance during anemia.
Nalbant D; Saleh M; Goldman FD; Widness JA; Veng-Pedersen P
J Pharmacol Exp Ther; 2010 May; 333(2):528-32. PubMed ID: 20103588
[TBL] [Abstract][Full Text] [Related]
14. EPO-independent functional EPO receptor in breast cancer enhances estrogen receptor activity and promotes cell proliferation.
Reinbothe S; Larsson AM; Vaapil M; Wigerup C; Sun J; Jögi A; Neumann D; Rönnstrand L; Påhlman S
Biochem Biophys Res Commun; 2014 Feb; 445(1):163-9. PubMed ID: 24502950
[TBL] [Abstract][Full Text] [Related]
15. Human recombinant erythropoietin does not promote cancer growth in presence of functional receptors expressed in cancer cells.
Belda-Iniesta C; Perona R; Carpeño Jde C; Cejas P; Casado E; Manguan-García C; Ibanez de Caceres I; Sanchez-Perez I; Andreu FB; Ferreira JA; Aguilera A; de la Peña J; Perez-Sánchez E; Madero R; Feliu J; Sereno M; González-Barón M
Cancer Biol Ther; 2007 Oct; 6(10):1600-5. PubMed ID: 17938574
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin ameliorates early brain injury after subarachnoid haemorrhage by modulating microglia polarization via the EPOR/JAK2-STAT3 pathway.
Wei S; Luo C; Yu S; Gao J; Liu C; Wei Z; Zhang Z; Wei L; Yi B
Exp Cell Res; 2017 Dec; 361(2):342-352. PubMed ID: 29102603
[TBL] [Abstract][Full Text] [Related]
17. Activation and inhibition of the erythropoietin receptor by a membrane-anchored erythropoietin.
Negre O; Fusil F; Henri A; Villette JM; Leboulch P; Beuzard Y; Payen E
Exp Hematol; 2008 Apr; 36(4):412-23. PubMed ID: 18295963
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation.
Veng-Pedersen P; Chapel S; Al-Huniti NH; Schmidt RL; Sedars EM; Hohl RJ; Widness JA
Biopharm Drug Dispos; 2004 May; 25(4):149-56. PubMed ID: 15108217
[TBL] [Abstract][Full Text] [Related]
19. The erythropoietin/erythropoietin receptor signaling pathway promotes growth and invasion abilities in human renal carcinoma cells.
Wu P; Zhang N; Wang X; Zhang C; Li T; Ning X; Gong K
PLoS One; 2012; 7(9):e45122. PubMed ID: 23028796
[TBL] [Abstract][Full Text] [Related]
20. Population Target-Mediated Pharmacokinetic/Pharmacodynamic Modeling to Evaluate SPI-62 Exposure and Hepatic 11β-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Inhibition in Healthy Adults.
Wu N; Katz DA; An G
Clin Pharmacokinet; 2023 Sep; 62(9):1275-1288. PubMed ID: 37452998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
